ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO018

International Multicenter Study to Investigate the Performance of Urinary L-FABP in Predicting COVID-19 Severity

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Katagiri, Daisuke, National center for Global Health and Medicine Hospital Department of Nephrology, Tokyo, Tokyo, Japan
  • Asai, Yusuke, National Center for Global Health and Medicine, DCC, Tokyo, Tokyo, Japan
  • Suzuki, Minami, National center for Global Health and Medicine Hospital Department of Nephrology, Tokyo, Tokyo, Japan
  • Takano, Hideki, National center for Global Health and Medicine Hospital Department of Nephrology, Tokyo, Tokyo, Japan
  • Miyashita, Yoshihiro, Department of Respiratory Medicine, Yamanashi Prefecture Central Hospital, Tokyo, Tokyo, Japan
  • Sugaya, Takeshi, Time Well Medical, Tokyo, Tokyo, Japan
  • Noiri, Eisei, National Center for Global Health and Medicine, Central Biobank, National Center Biobank Network, Tokyo, Tokyo, Japan
Background

Early detection of the illness trajectory in SARS-CoV-2 infected patients is crucial for patients and healthcare workers. A practical, non-invasive approach, with simple measurement for decision-making, is necessary for a pandemic to discriminate between high and low-risk patients, even though both may appear mild initially.

Methods

To determine COVID-19 disease severity within 10-days, distinguishing severe vs. moderate+mild and severe+moderate vs. mild, urinary L-type fatty acid-binding protein (L-FABP) was assayed less than four days after receiving a diagnosis. Severity was divided into mild (without oxygen), moderate (with oxygen) and severe (IMV/ECMO), and L-FABP within four days of diagnosis were used to predict severity within 10 days after onset. For risk prediction, urinary L-FABP was compared with interleukin-6. Next, the L-FABP point-of-care test (POCT) was further examined for its utility in risk screening in the international multicenter study.

Results

Of the 224 participants in the study, 173 initially had a mild form. The AUC for a severe outcome was 96.3% in creatinine-adjusted L-FABP and 93.5% in net value. The AUC for a mild outcome was 85.0% and 84.9% net. The predictability of L-FABP for either a severe or mild outcome was superior to that of IL-6. Dynamics further showed better predictability of L-FABP than IL-6 during 10-days after onset. Finally, a multicenter-multicountry study confirmed the L-FABP POCT risk prediction of a severe outcome with an AUC of 88.9% and a mild outcome of 68.5%.

Conclusion

Urinary L-FABP can predict the patient's risk of illness severity in COVID-19. L-FABP may detect severe cases more effectively and earlier than IL-6. L-FABP POCT is implementable for patient management.

Funding

  • Government Support – Non-U.S.